Brazilian generic industry review

The Brazilian pharmaceutical market is growing rapidly into one of the largest pharma markets in the world. Unbranded and branded generics are among the fastest growing segments within this market, according to a new report added to the offering of ResearchandMarkets.

For 2012, IMS monetary values for the prescription market were around $26 billion, with unbranded and branded generics representing an approximate combined 40% share, and over 1.2 billion manufacturing units with unbranded and branded generics representing a combined 50% share, showing a growing trend. For unbranded generics alone, the market counts on 400 different actives spread over 4000 individual registration approvals with approx. 18,000 different presentations, with solid perspectives of continued strong growth.

Ever since the genesis of the Brazilian unbranded generics segment in 2000, the interest of international suppliers and manufacturers of non-patented formulations in the Brazilian market has grown steadily and significantly, the report notes. However, as they start to deal with the local business and institutional culture, most of these companies face serious and unexpected difficulties.